Trials / Conditions / Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

16 registered clinical trials studyying Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients NCT06513949	Implicit Bioscience	Phase 2
Recruiting	VExUS in Ards Patients and Association with AKI NCT06805409	Assistance Publique - Hôpitaux de Paris	—
Unknown	Evaluation of VQm PHM on Pulmonary Health Parameters for ICU NCT06147674	Rostrum Medical Innovations Inc.	—
Recruiting	ALI/ARDS Clinical Sub-phenotyping Study NCT06123962	China-Japan Friendship Hospital	—
Unknown	FSTL1 and PPCs on Pediatric Within LDLT:a Prospective Cohort Analysis NCT05807802	Tianjin First Central Hospital	—
Recruiting	Infants with Severe Acute Respiratory Distress Syndrome: the Prone Trial NCT05002478	Medical University of Vienna	N/A
Unknown	Improvement of Pulmonary Insufficiency After Aortic Dissection With Sivelestat Sodium NCT05343338	First Affiliated Hospital Xi'an Jiaotong University	N/A
Unknown	Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS NCT05153525	Tanta University	Phase 4
Withdrawn	Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 NCT05137795	APR Applied Pharma Research s.a.	Phase 3
Completed	Non-invasive Vagal Neurostimulation (nVNS) for Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress NCT04935697	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	N/A
Withdrawn	Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS NCT04482712	The University of Texas Health Science Center at San Antonio	Phase 1 / Phase 2
Terminated	Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 NCT04360096	APR Applied Pharma Research s.a.	Phase 2 / Phase 3
Completed	The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (CO NCT04389671	Windtree Therapeutics	Phase 2
Completed	Mechanism of Delayed Neutrophil Apoptosis in Acute Lung Injury NCT04607434	The First Hospital of Jilin University	—
Completed	Rehabilitation for People With COVID-19 in ICU NCT04381338	University of Padova	N/A
No Longer Available	SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 NCT04355494	Alexion Pharmaceuticals, Inc.	—